These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

23 related articles for article (PubMed ID: 16475914)

  • 1. Blood, the hidden side of myeloma?
    Corre J
    Blood; 2024 Jun; 143(23):2344-2345. PubMed ID: 38842860
    [No Abstract]   [Full Text] [Related]  

  • 2. Systemic levels of interleukin-6 and matrix metalloproteinase-9 in patients with multiple myeloma may be useful as prognostic indexes of bone disease.
    Sfiridaki A; Miyakis S; Tsirakis G; Alegakis A; Passam AM; Kandidaki E; Margioris AN; Alexandrakis MG
    Clin Chem Lab Med; 2005; 43(9):934-8. PubMed ID: 16176173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High serum levels of complements C3 and C4 as novel markers for myeloma bone disease.
    Jiang F; Liu H; Liu Z; Song J; Li L; Ding K; Ren Y; Peng F; Shao Z; Fu R
    Ann Hematol; 2017 Feb; 96(2):331-333. PubMed ID: 27924370
    [No Abstract]   [Full Text] [Related]  

  • 4. Monitoring myelomatosis.
    Hobbs JR
    Arch Intern Med; 1975 Jan; 135(1):125-30. PubMed ID: 1111461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The diagnostic value of monoclonal proteins in serum].
    Erikssen J; Lingjaerde P
    Tidsskr Nor Laegeforen; 1973 Sep; 93(25):1733-6. PubMed ID: 4771905
    [No Abstract]   [Full Text] [Related]  

  • 6. Multiple-myeloma: review of 231 cases.
    Advani SH; Soman CS; Talwalkar GV; Lyer YS; Bhatia HM
    Indian J Cancer; 1978 Jun; 15(2):55-61. PubMed ID: 374240
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma.
    Lipton A; Cook RJ; Coleman RE; Smith MR; Major P; Terpos E; Berenson JR
    Clin Lymphoma Myeloma; 2007 Mar; 7(5):346-53. PubMed ID: 17562244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Matrix Metalloproteinase-9 (MMP-9) as a Prognostic Factor in Epithelial and Lymphatic Neoplasia.
    Pârvănescu V; Georgescu M; Georgescu I; Șurlin V; Pătraşcu Ș; Picleanu AM; Georgescu E
    Chirurgia (Bucur); 2015; 110(6):506-10. PubMed ID: 26713823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solitary plasmacytoma of bone and asymptomatic multiple myeloma.
    Dimopoulos MA; Moulopoulos A; Delasalle K; Alexanian R
    Hematol Oncol Clin North Am; 1992 Apr; 6(2):359-69. PubMed ID: 1582978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic matrix metalloproteinase-9 (MMP-9) levels as prognostic indexes of bone disease in patients with multiple myeloma.
    Demacq C; Montenegro MF
    Clin Chem Lab Med; 2006; 44(2):232; author reply 233. PubMed ID: 16475914
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.